Avingtrans Plc Adaptix appoints Willem Baralt as new Chairman

Avingtrans plc

Avingtrans PLC (LON:AVG) has announced that further to the statement made on 14 December 2022, Adaptix, the Oxford based emerging MedTech Company, has appointed Willem Baralt as its new Chairman. Willem, previously of Quanta Dialysis Technologies, will succeed Steve McQuillan (CEO of Avingtrans), who was appointed to the Board of Adaptix in December 2022 in an interim capacity. Steve will continue as a Non-Executive Director of Adaptix.

In 2021, Avingtrans plc invested £4m in Adaptix, for an 11.9% stake in the business and in December 2022 announced a further investment of £2m by means of a Convertible Loan Note.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
    Avingtrans PLC reports strong performance in H1 2024, with expectations aligned across energy, medical, and industrial sectors. Growth anticipated in FY25.
    Avingtrans plc's Adaptix, an innovator in 3D X-Ray imaging, wins Aerospace Technology Innovation Award for its breakthrough in non-destructive testing.
    Avingtrans plc CEO Steve McQuillan discusses preliminary results for the year ended 31 May 2024, highlighting record sales, strategic acquisitions, and future growth.
    Avingtrans PLC (LON:AVG) announces a remarkable 17.3% revenue increase to £136.6m for the year ended 31 May 2024, highlighting strategic investments and robust growth across energy and medical sectors.
    Avingtrans PLC (LON:AVG) reports record revenue and adjusted EBITDA ahead of expectations for the financial year ending 31 May 2024, with strong growth across its divisions.
    Avingtrans plc CEO Steve McQuillan discusses interim results, acquisitions, and company restructuring in an exclusive interview with DirectorsTalk.

      Search

      Search